Dengue Vaccine QDENGA Approved in India

|

Dengue Vaccine QDENGA Approved in India

Science & Technology
Dengue Vaccine QDENGA Approved in India

The Drug Controller General of India (DCGI) grants market authorisation to Takeda Biopharmaceuticals India’s QDENGA (TAK‑003), making it the first dengue vaccine approved in India. The approval covers its vaccine type, dosage schedule, eligible age group, and administration requirement regarding pre-vaccination screening.

QDENGA (TAK‑003) Dengue Vaccine:

Dimension Key Details
Type QDENGA is a live-attenuated tetravalent vaccine.
Protection Coverage QDENGA provides for protection against all 4 dengue virus serotypes.
Dosage and Route Dosage comprises 2 subcutaneous injections of 0.5 ml each, given 3 months apart.
Approved Age Group QDENGA applies to individuals aged 4 to 60 years.
Pre-vaccination Screening QDENGA does not require pre-vaccination dengue screening.
WHO Recommendation WHO recommendation applies to dengue-endemic regions with high transmission.
WHO Prequalification WHO prequalification authorises procurement by UNICEF and PAHO.
Global Approvals QDENGA is licensed in 43 countries across Asia, Latin America, and Europe.
Did you find this informative?

Attempt Possible Qs

Q 1 / 3
With reference to QDENGA (TAK-003) dengue vaccine, consider the following statements:
1. It provides protection against all 4 dengue virus serotypes.
2. It is administered as 2 subcutaneous injections of 0.5 ml each.
3. The 2 doses are given 6 months apart.
Which of the statements given above are correct?